An AIE-based self-assembled fluorescent probe for COX-2 imaging. (9th May 2019)

• Record Type: Journal Article
• Authors: Cao, Xiaozheng; Gao, Tang; Dong, Jie; Jiang, Xinchen; Zou, Hui; Liu, Tingting; Yu, Kunqian; Zeng, Wenbin
• Is Part Of: New journal of chemistry. Volume 43:Number 20(2019)
• Page Start: 7874
• Page End: 7880
• Publication Date: 2019-05-09
• Subjects: Chemistry -- Periodicals; Chimie -- Périodiques; 540
• DOI: 10.1039/c9nj01473j
• Languages: English
• ISSNs: 1144-0546

Abstract

Abstract : The first AIE-based fluorescent probeTPI-IMC was developed for imaging of cyclooxygenase-2 (COX-2) in normal cells and cancer cells. Abstract : Cyclooxygenase-2 (COX-2), an isozyme of the cyclooxygenase enzyme family, is not only highly expressed in various types of tumors, but also over-expressed in all stages of cancer. Herein, we report the design and preparation of an aggregation-induced emission (AIE) based fluorescent probeTPI-IMC for the imaging of COX-2 by the conjugation of 4-(1, 4, 5-triphenyl-1 H -imidazol-2-yl)pyridine (TPI) and COX-2 inhibitor indomethacin (IMC). The probe was applied for the detection and imaging of COX-2, and a linear range from 0 to 0.4 μg mL −1 and a detection limit of 0.08 μg mL −1 in vitro were achieved.TPI-IMC exhibits weak fluorescence in normal cells (LO2 cells andRAW264.7 cells), while it exhibits stronger fluorescence in the cells over-expressing COX-2 such as cancer cells (HeLa cells) and inflammatory cells (LPS induced RAW264.7 cells). It is also found that significantly reduced fluorescence intensity is observed and detected in HeLa cells co-treated with the COX-2 inhibitor celecoxib. Therefore, TPI-IMC has the potential to be used as a guiding-agent in surgery for tumours and inflammation.